This week, drug maker Sanofi filed a patent infringement suit against Mylan in a New Jersey district court. Sanofi’s suit alleges that Mylan has infringed on 18 patents for its originator insulin glargine, Lantus.
This week, drug maker Sanofi filed a patent infringement suit against Mylan in a New Jersey district court. Sanofi’s suit alleges that Mylan has infringed on 18 patents for its originator insulin glargine, Lantus.
The suit was triggered by Mylan’s filing of a New Drug Application (NDA) with the FDA for a pre-filled pen and a drug vial presentation of a follow-on insulin glargine (in the United States, insulins are regulated as drugs and not as biologics; hence, drug makers must submit NDAs rather than biologics license applications for follow-ons of originator products). According to Sanofi, the Mylan NDA included a challenge to all of Sanofi’s patents listed for Lantus in the FDA’s orange book.
Mylan’s filing of an NDA for its proposed insulin glargine follows the recent release of data demonstrating comparable efficacy, safety, and immunogenicity with Lantus, as well as the follow-on’s pharmacokinetic and pharmacodynamic equivalence with the reference drug. Mylan, working together with India-based partner Biocon, is also seeking European approval for its product; in September, Biocon received a certificate of compliance from the European Union for its manufacturing facility in Malaysia where it plans to produce the insulin. Approval of the facility was welcome news for Biocon; high operational costs related to the Malaysian facility had been partially responsible for a 51% drop in Biocon’s second-quarter net profits, despite the company’s strong sales of insulins.
Sanofi faces challenges from other drug developers who seek a share of the Lantus market; in July, the FDA granted Merck’s follow-on insulin glargine a tentative approval, but will not provide the drug with a final approval until patent litigation, brought by Sanofi, has concluded. Sanofi’s suit triggered an automatic stay of 30 months.
Already on the US market is Boehringer Ingelheim’s (BI) Basaglar, the first FDA-approved insulin glargine follow-on, which launched in 2016 after a lengthy patent litigation with Sanofi. Competition from Basaglar led to steep declines in insulin market share for Sanofi in the second quarter of 2017; Sanofi’s US sales of Lantus and Toujeo (a second insulin glargine) dropped by 23.9%. CEO Oliver Brandicourt has alerted investors that the company’s fortunes were unlikely to change in the remainder of 2017, and warned that the company could see accelerated declines in sales of its insulins as it faced further competition.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.